UCB Raises Annual Guidance for Second Time This Year; Shares Jump 13%
UCB cited strong U.S. demand for its Bimzelx drug as it raised annual guidance for the second time this year. Shares rose 13% in European morning trading, erasing year-to-date losses.
UCB shares climbed after the Belgian pharmaceutical company lifted its annual guidance for the second time this year, pointing to strong U.S. demand for its blockbuster drug Bimzelx. The stock was up 13% in European morning trading, wiping out its losses for the year to date. If maintained u…